While apabetalone failed to diminish ischemic cardiovascular events in this patient population, the BET inhibitor was found to be well-tolerated, and secondary subgroup analyses revealed a reduction in hospitalizations for heart failure in patients with T2D and recent ACS[8], and fewer heart failure-related hospitalizations in patients with chronic kidney disease and T2D[9]. This evidence concerns the gene DNER and type 2 diabetes mellitus.